Colorectal Cancer Clinical Trials in Nashville, Tennessee

32 studies are recruiting for colorectal cancer in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

1. Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

   This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee

   Locations

   15 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT03947385 on ClinicalTrials.gov

2. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

   This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   14 in total

   Run by

   Verastem, Inc.

   See if you can join NCT07020221 on ClinicalTrials.gov

3. Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients

   RATIONALE: Studying samples of tissue, blood, urine, stool, and other biological fluids from patients with cancer and from healthy volunteers undergoing colonoscopy or endoscopy may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This research study is looking at g…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Veterans Affairs Medical Center - Nashville, Nashville, Tennessee

   Locations

   2 in total

   Run by

   Vanderbilt University Medical Center

   See if you can join NCT00899626 on ClinicalTrials.gov

4. A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

   The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.

   Stage

   Phase 1

   Ages

   18 to 85

   Site

   Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   4 in total

   Run by

   Chimeric Therapeutics

   See if you can join NCT06055439 on ClinicalTrials.gov

5. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

   This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gast…

   Stage

   Not phased

   Ages

   40 and older

   Site

   Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

   Locations

   17 in total

   Run by

   Adela, Inc

   See if you can join NCT05366881 on ClinicalTrials.gov

6. Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

   The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Locations

   20 in total

   Run by

   Bicara Therapeutics

   See if you can join NCT04429542 on ClinicalTrials.gov

7. Preserving Fertility After Colorectal Cancer Study

   The PREFACE Study is a prospective, longitudinal cohort study of reproductive health and clinical outcomes among individuals diagnosed with colorectal cancer between age 18 to 49 years.

   Stage

   Not phased

   Ages

   18 to 49

   Site

   Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

   Run by

   Andreana Holowatyj, PhD, MSCI

   See if you can join NCT05239338 on ClinicalTrials.gov